James Liao to Cardiovascular Diseases
This is a "connection" page, showing publications James Liao has written about Cardiovascular Diseases.
Connection Strength
4.092
-
Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022 01 29; 118(2):413-423.
Score: 0.521
-
Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Expert Opin Ther Targets. 2020 01; 24(1):47-62.
Score: 0.452
-
Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017 Jan 06; 120(1):229-243.
Score: 0.367
-
Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation. 2011 May 10; 123(18):1925-8.
Score: 0.247
-
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J. 2010 May; 74(5):818-26.
Score: 0.230
-
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal. 2009 Mar 17; 2(62):ra11.
Score: 0.214
-
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15(5):467-78.
Score: 0.211
-
Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007 Jul; 50(1):17-24.
Score: 0.190
-
Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol. 2007 Apr 17; 49(15):1619-1624.
Score: 0.186
-
ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther. 2005 May; 3(3):441-51.
Score: 0.163
-
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118.
Score: 0.160
-
Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003 Sep; 5(5):372-8.
Score: 0.145
-
Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002 Nov; 86(1):5-18.
Score: 0.137
-
Non-nuclear actions of estrogen: new targets for prevention and treatment of cardiovascular disease. Mol Interv. 2002 Jul; 2(4):219-28.
Score: 0.134
-
SALAD-BAAR: A numerical risk score for hospital admission or emergency department presentation in ambulatory patients with cardiovascular disease. Clin Cardiol. 2021 Feb; 44(2):193-199.
Score: 0.122
-
Targeting Rho in cardiovascular disease. Circ Res. 2000 Sep 29; 87(7):526-8.
Score: 0.119
-
Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice. Circ J. 2018 03 23; 82(4):1195-1204.
Score: 0.099
-
Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension. 2014 Apr; 63(4):856-64.
Score: 0.074
-
Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011 Oct; 31(10):2353-9.
Score: 0.063
-
Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011 Mar; 32(3):167-73.
Score: 0.061
-
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 2010 Aug; 15(15-16):622-9.
Score: 0.058
-
Does it matter whether or not a lipid-lowering agent inhibits Rho kinase? Curr Atheroscler Rep. 2007 Nov; 9(5):384-8.
Score: 0.049
-
Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006 Mar; 290(3):C661-8.
Score: 0.043
-
Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002 Aug; 110(3):285-8.
Score: 0.034
-
Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis. 2011 Jan; 214(1):117-21.
Score: 0.015